Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enablers and barriers of e-learning utilising smart technologies in type 2 diabetes care for clinicians: a systematic review.

BMJ open·2025
Same author

Subclinical hyperthyroidism.

Current opinion in endocrinology, diabetes, and obesity·2025
Same author

British Thyroid Association Survey of Graves' Disease Management in the UK.

Clinical endocrinology·2025
Same author

Conservatively managed non-functioning pituitary macroadenomas-cohort study from the UK Non-functioning Pituitary Adenoma Consortium.

European journal of endocrinology·2025
Same author

Protocol for the implementation and referral of the ecofit physical activity intervention within Diabetes Alliance Program Plus among regional, rural and remote people with type 2 diabetes in a primary care setting.

Contemporary clinical trials·2024
Same author

The Role of Smartwatch Technology in the Provision of Care for Type 1 or 2 Diabetes Mellitus or Gestational Diabetes: Systematic Review.

JMIR mHealth and uHealth·2024

Related Experiment Videos

Current and emerging treatment options for Graves' hyperthyroidism.

Prakash Abraham1, Shamasunder Acharya

  • 1Department of Endocrinology, Aberdeen Royal Infirmary, Aberdeen, UK;

Therapeutics and Clinical Risk Management
|February 20, 2010
PubMed
Summary
This summary is machine-generated.

Graves

Keywords:
Graves’ hyperthyroidismantithyroid drugsmethimazolepropylthiouracilradioiodine

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Internal Medicine

Background:

  • Graves' hyperthyroidism has established treatments like radioiodine, antithyroid drugs, and surgery.
  • Significant variations exist in treatment modality and administration methods among physicians.
  • Patient preferences and perceptions influence treatment selection.

Purpose of the Study:

  • To review current evidence and comparative benefits of established and emerging therapies for Graves' hyperthyroidism.
  • To discuss treatment administration variations, risks, and special considerations.
  • To explore novel immunomodulatory treatments and clinical practice influences.

Main Methods:

  • Review of established therapies: radioiodine (fixed vs. calculated doses) and antithyroid drugs (block-replace vs. titration regimens).
  • Discussion of radioiodine risks (e.g., eye disease) and steroid prophylaxis.
  • Examination of emerging treatments, including immunomodulatory agents like rituximab.
  • Consideration of antithyroid therapies in special situations and clinical practice issues.

Main Results:

  • Established therapies (radioiodine, antithyroid drugs, surgery) show varied application and administration.
  • Radioiodine carries risks, including potential eye disease, with steroid prophylaxis debated.
  • Antithyroid drugs are administered via different dosing strategies (block-replace or titration).

Conclusions:

  • Treatment choice for Graves' hyperthyroidism involves established modalities, physician practice variations, and patient factors.
  • Emerging immunomodulatory therapies like rituximab show early promise.
  • Optimizing treatment requires considering evidence, risks, and individual patient circumstances.